Elevance Health, Inc. · NYSE (us_market)
Healthcare · Healthcare Plans · United States
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-15$381.93 RISE2026-03-09$280.74 PEAK2026-05-19$402.27 124d | -26.5% 53d | Missed | Missed | — | — | +43.3% 71d | Missed |
DROP2025-10-08$362.34 RISE2025-11-10$303.78 PEAK2026-01-15$381.93 99d | -16.2% 33d | Missed | Missed | — | — | +25.7% 66d | Missed |
DROP2025-04-03$452.69 RISE2025-08-01$274.66 PEAK2025-10-08$362.34 188d | -39.3% 120d | Missed | Missed | — | — | +31.9% 68d | Missed |
DROP2024-10-14$509.02 RISE2025-02-18$382.48 PEAK2025-04-03$452.69 171d | -24.9% 127d | Missed | Missed | — | — | +18.4% 44d | Missed |
DROP2024-09-03$562.29 RISE2025-01-02$365.83 PEAK2025-03-18$436.25 196d | -34.9% 121d | Missed | Missed | — | — | +19.2% 75d | Missed |
DROP2021-01-11$338.77 RISE2021-02-08$287.70 PEAK2021-05-04$391.67 113d | -15.1% 28d | Missed | Missed | — | — | +36.1% 85d | Missed |
DROP2020-06-08$300.59 RISE2020-09-23$245.73 PEAK2020-11-16$333.15 161d | -18.3% 107d | Missed | Missed | — | — | +35.6% 54d | Missed |
DROP2020-01-10$307.74 RISE2020-03-23$174.68 PEAK2020-06-08$300.59 150d | -43.2% 73d | Missed | Missed | — | — | +72.1% 77d | Missed |
Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index decreasing 0.8% and
Avantor (AVTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
As UnitedHealth Group has considerably outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.
Elevance Health (ELV) has drawn investor attention after recent share price moves, with the stock closing at US$391.47. That performance comes alongside reported annual revenue of US$200.4b and net income of US$5.2b. See our latest analysis for Elevance Health. Beyond the latest move to US$391.47, Elevance Health has seen a 9.92% 1 month share price return and a 21.18% 3 month share price return, while the 3 year total shareholder return is down 8.26%. This highlights shorter term momentum...
Over the last year, a good number of insiders have significantly increased their holdings in Elevance Health, Inc...
Elevance Health, Inc. (NYSE:ELV) is included among the 10 Best Blue Chip Stocks to Buy for Your Retirement Portfolio. On May 22, UBS raised its price recommendation on Elevance Health, Inc. (NYSE:ELV) to $460 from $400. It reiterated a Buy rating on the shares. The firm said managed care organizations broadly increased guidance after stronger-than-expected […]
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.61%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.76%. June E-mini S&P futures (ESM26 ) rose +0.61%, and June E-mini Nasdaq futures...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.81%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.74%. June E-mini S&P futures (ESM26 ) are up +0.77%, and June E-mini Nasdaq futures...
Go beyond the broad index and find which segment of healthcare best suits your portfolio needs now.
Go beyond the broad index and find which segment of healthcare best suits your portfolio needs now.
Earlier this week, Elevance Health reported stronger-than-expected FY2026 Q1 results and raised its full-year adjusted EPS guidance, while its Chief Accounting Officer Ronald W. Penczek exercised and sold 1,531 fully vested stock options at US$403.13 per share, leaving him with 4,109 directly held shares. The upbeat earnings report, higher guidance, and supportive analyst commentary on margins and valuation have reinforced investor attention on Elevance Health’s operational execution and...
Earlier this week, Elevance Health reported stronger-than-expected FY2026 Q1 results and raised its full-year adjusted EPS guidance, while its Chief Accounting Officer Ronald W. Penczek exercised and sold 1,531 fully vested stock options at US$403.13 per share, leaving him with 4,109 directly held shares. The upbeat earnings report, higher guidance, and supportive analyst commentary on margins and valuation have reinforced investor attention on Elevance Health’s operational execution and...
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Elevance has lagged behind the broader market over the past year, yet analysts remain reasonably optimistic about the stock’s prospects.
Elevance has lagged behind the broader market over the past year, yet analysts remain reasonably optimistic about the stock’s prospects.
UBS analyst A.J. Rice maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $400 to $460.
Cigna downgraded, Humana upgraded: Wall Street's top analyst calls
Investing.com -- Analysts at Deutsche Bank turned more bullish on the managed care sector, upgrading shares of Humana, Centene, and Elevance Health to “Buy,” while downgrading The Cigna Group to “Hold” on valuation concerns.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ELV | +5.50% | +33.71% | +12.16% | +2.44% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +2.53% | +39.42% | +15.61% | -10.25% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 10.29M | $3.01B | 0.10% | Trimmed-0.5% | 2026-03-31 |
| Wellington | fundamental | 8.23M | $2.41B | 0.45% | Trimmed-0.7% | 2026-03-31 |
| FidelityFMR | fundamental | 1.98M | $578.39M | 0.03% | Added+33.6% | 2026-03-31 |
| DEShaw | quant | 406.0K | $118.85M | 0.07% | Trimmed-17.5% | 2026-03-31 |
| CapResearch | fundamental | 119.1K | $34.86M | 0.01% | Trimmed-1.2% | 2026-03-31 |
| Citadel | multi-strat | 59.3K | $17.37M | 0.02% | New | 2026-03-31 |
| RenTech | quant | 15.6K | $4.56M | 0.01% | New | 2026-03-31 |
| TRowePrice | fundamental | 4.75M | $1.39M | 0.16% | Trimmed-36.3% | 2026-03-31 |
| TwoSigma | quant | 1.3K | $368.87K | 0.00% | New | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-20 | Penczek Ronald W | CAO & Controller | M Option exercise(deriv) | 877 | — | +$0 |
| 2026-05-20 | Penczek Ronald W | CAO & Controller | M Option exercise(deriv) | 654 | — | +$0 |
| 2026-05-20 | Penczek Ronald W | CAO & Controller | S Open-market sale | 1,531 | $403.13 | −$617.2K |
| 2026-05-20 | Penczek Ronald W | CAO & Controller | M Option exercise | 877 | $311.48 | +$273.2K |
| 2026-05-20 | Penczek Ronald W | CAO & Controller | M Option exercise | 654 | $271.27 | +$177.4K |
| 2026-05-15 | COLLIS STEVEN H | Director | A Grant / award | 563 | — | +$0 |
| 2026-05-15 | DeVore Susan D. | Director | A Grant / award | 563 | — | +$0 |
| 2026-05-15 | Dixon Robert L JR | Director | A Grant / award | 563 | — | +$0 |
| 2026-05-15 | HAY LEWIS III | Director | A Grant / award | 563 | — | +$0 |
| 2026-05-15 | Jallal Bahija | Director | A Grant / award | 563 | — | +$0 |
| 2026-05-15 | Neri Antonio F | Director | A Grant / award | 563 | — | +$0 |
| 2026-05-15 | PERU RAMIRO G | Director | A Grant / award | 563 | — | +$0 |
| 2026-05-15 | Schneider Ryan M. | Director | A Grant / award | 563 | — | +$0 |
| 2026-05-15 | SCHULMAN AMY W | Director | A Grant / award | 563 | — | +$0 |
| 2026-05-15 | STRABLE-SOETHOUT DEANNA D | Director | A Grant / award | 563 | — | +$0 |
| 2026-03-23 | SCHULMAN AMY W | Director | S Open-market sale | 26 | $287.50 | −$7.5K |
| 2026-03-09 | Kendrick Charles Morgan JR | EVP & President, Commercial | S Open-market sale | 3,196 | $284.92 | −$910.6K |
| 2026-03-06 | COLLIS STEVEN H | Director | P Open-market purchase | 3,000 | $289.84 | +$869.5K |
| 2026-03-04 | BOUDREAUX GAIL | President and CEO | A Grant / award(deriv) | 63,818 | — | +$0 |
| 2026-03-04 | BOUDREAUX GAIL | President and CEO | F Tax withholding | 1,736 | $284.03 | −$493.1K |
| 2026-03-04 | BOUDREAUX GAIL | President and CEO | A Grant / award | 10,527 | — | +$0 |
| 2026-03-04 | BOUDREAUX GAIL | President and CEO | A Grant / award | 16,153 | — | +$0 |
| 2026-03-04 | BOUDREAUX GAIL | President and CEO | F Tax withholding | 6,713 | $294.07 | −$1.97M |
| 2026-03-04 | Kaye Mark | EVP & CFO | A Grant / award(deriv) | 25,188 | — | +$0 |
| 2026-03-04 | Kaye Mark | EVP & CFO | F Tax withholding | 353 | $284.03 | −$100.3K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-16upcoming | 6.20 | — | — |
| 2026-04-22 | 10.81 | 12.58 | +16.36% |
| 2026-01-28 | 3.09 | 3.33 | +7.65% |
| 2025-10-21 | 4.94 | 6.03 | +22.01% |
| 2025-07-17 | 8.92 | 8.84 | -0.91% |
| 2025-04-22 | 11.48 | 11.97 | +4.30% |
| 2025-01-23 | 3.85 | 3.84 | -0.29% |
| 2024-10-17 | 9.65 | 8.37 | -13.28% |
| 2024-07-17 | 10.01 | 10.12 | +1.14% |
| 2024-04-18 | 10.53 | 10.64 | +1.08% |
| 2024-01-24 | 5.59 | 5.62 | +0.62% |
| 2023-10-18 | 8.46 | 8.99 | +6.27% |
| 2023-07-19 | 8.78 | 9.04 | +2.95% |
| 2023-04-19 | 9.28 | 9.46 | +1.97% |
| 2023-01-25 | 5.19 | 5.23 | +0.75% |
| 2022-10-19 | 7.15 | 7.53 | +5.29% |